Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

Marzullo, P; Daffara, T; Mele, C; Zavattaro, M; Ferrero, A; Caputo, M; Prodam, F; Aimaretti, G

Marzullo, P; Daffara, T; Mele, C; Zavattaro, M; Ferrero, A; Caputo, M; Prodam, F; Aimaretti, G.

Affiliation

Marzullo P; Department of Translational Medicine, Università del Piemonte Orientale, Via Solaroli 17, 28100, Novara, Italy. paolo.marzullo@med.uniupo.it.
Daffara T; Laboratory of Metabolic Diseases, IRCCS, Istituto Auxologico Italiano, Piancavallo, Verbania, Italy. paolo.marzullo@med.uniupo.it.
Mele C; Endocrinology and Diabetes Unit, AOU Ospedale Maggiore Della Carità, Novara, Italy.
Zavattaro M; Department of Translational Medicine, Università del Piemonte Orientale, Via Solaroli 17, 28100, Novara, Italy.
Ferrero A; Endocrinology and Diabetes Unit, AOU Ospedale Maggiore Della Carità, Novara, Italy.
Caputo M; Endocrinology and Diabetes Unit, AOU Ospedale Maggiore Della Carità, Novara, Italy.
Prodam F; Endocrinology and Diabetes Unit, AOU Ospedale Maggiore Della Carità, Novara, Italy.
Aimaretti G; Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.

J Endocrinol Invest ; 45(8): 1587-1598, 2022 Aug.

Article de En | MEDLINE | ID: mdl-35429298

Sujet(s)
Mots clés

GLP-1 receptor agonists; Obesity; Once-weekly semaglutide; Type 2 diabetes mellitus

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: J Endocrinol Invest Année: 2022 Type de document: Article Pays d'affiliation: Italie Pays de publication: Italie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google